AOD-9604 is a peptide fragment from the C-terminal region of human growth hormone, which is being studied in experiments mainly in relation to lipolysis, fat metabolism and energy homeostasis.
Concentration (test)
Unspecified
Packaging
Glass vial with sterile closure (5 mg powder)
Storage
2–8 °C, protect from moisture and light
Molecular formula
Unspecified
Molecular weight
Unspecified
Other names
HGH fragment 176–191, AOD-9604
In laboratory studies, AOD-9604 is associated with research in areas such as:
- lipolysis and mobilization of fatty acids in adipocytes,
- inhibition of lipogenesis and regulation of adipogenesis,
- metabolic flexibility and glucose-insulin response parameters,
- body composition and energy expenditure in experimental models,
- study of cartilage and soft tissues in the context of cytoprotection.
This content is for educational purposes only. It is not a recommendation for human use. The substance is intended for laboratory research only.
What is AOD-9604
AOD-9604 is a short peptide derived from the 176–191 fragment of human growth hormone. It is being studied in model systems for its potential to affect lipid metabolism without the typical side effects of full-length GH in the IGF-1 axis. From a scientific perspective, it is a tool for investigating the pathways controlling lipolysis, energy balance, and changes in adipose tissue.
How AOD-9604 works
In cell and tissue models, activation of lipolytic mechanisms (cAMP/PKA) is observed with subsequent modulation of enzymes such as hormone-sensitive lipase and adipocyte triacylglycerol lipase. In parallel, inhibition of lipogenesis and signaling pathways supporting the storage of triacylglycerols is observed. The described effects are investigated primarily in adipocytes and liver models.
Researched effects and interesting facts
-
Lipolysis and fat oxidation: monitoring the release of fatty acids and their use as an energy source.
-
Inhibition of lipogenesis: impact on fatty acid and triacylglycerol synthesis pathways in adipocytes.
-
Metabolic markers: changes in the levels of selected metabolic parameters in experimental protocols.
-
Body composition: tracking the ratio of fat and lean mass in energy balance models.
-
Tissue cytoprotection: investigating markers of cartilage and soft tissue integrity.
Dosage in studies
-
Dose: Not specified (low microgram ranges are used in the literature according to study objective and biomarkers).
-
Form: subcutaneously or intramuscularly after preparation of solution from lyophilized powder.
-
Frequency: Unspecified (defined by experimental design).
-
Duration: Unspecified (short-term and longer protocols depending on the parameters monitored).
The information provided is based on research protocols and publications. It is not intended for real-world use outside of a laboratory setting.
Possible side effects (injectable form)
- local irritation, redness or tenderness at the injection site,
- transient hot flashes, slight drop in blood pressure or dizziness,
- rarely nausea or discomfort in the digestive tract.
Resources
- Review publications on GH fragments (176–191) and their lipolytic mechanisms in adipocytes.
- Experimental studies monitoring cAMP/PKA signaling, HSL/ATGL, and lipid metabolism parameters.
- Works evaluating the effect of GH peptide fragments on body composition and energy homeostasis in models.
This article is for informational purposes only. It does not constitute a recommendation or solicitation for use. The information provided is for educational purposes within the framework of laboratory research.
Sale
